DAL MASO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.105
AS - Asia 2.405
EU - Europa 1.243
SA - Sud America 338
AF - Africa 327
Continente sconosciuto - Info sul continente non disponibili 63
OC - Oceania 42
Totale 7.523
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.850
SG - Singapore 644
VN - Vietnam 546
IT - Italia 491
CN - Cina 389
HK - Hong Kong 208
BR - Brasile 204
BD - Bangladesh 157
FR - Francia 89
DE - Germania 88
GB - Regno Unito 72
IN - India 65
NL - Olanda 65
SE - Svezia 61
FI - Finlandia 58
CA - Canada 57
PL - Polonia 52
IQ - Iraq 39
TR - Turchia 32
AR - Argentina 30
MX - Messico 29
RU - Federazione Russa 27
JP - Giappone 22
PK - Pakistan 22
SA - Arabia Saudita 22
CO - Colombia 21
CR - Costa Rica 20
ID - Indonesia 19
ZA - Sudafrica 19
EC - Ecuador 18
JM - Giamaica 18
KR - Corea 18
PH - Filippine 18
BJ - Benin 16
ES - Italia 16
IL - Israele 16
AU - Australia 14
MA - Marocco 14
AE - Emirati Arabi Uniti 13
AT - Austria 13
DO - Repubblica Dominicana 13
PT - Portogallo 13
TN - Tunisia 13
VE - Venezuela 13
AZ - Azerbaigian 12
CL - Cile 12
GR - Grecia 12
IE - Irlanda 12
JO - Giordania 12
NI - Nicaragua 12
TT - Trinidad e Tobago 12
AL - Albania 11
AO - Angola 11
CH - Svizzera 11
DZ - Algeria 11
LC - Santa Lucia 11
RE - Reunion 11
TJ - Tagikistan 11
UA - Ucraina 11
UZ - Uzbekistan 11
XK - ???statistics.table.value.countryCode.XK??? 11
AF - Afghanistan, Repubblica islamica di 10
CZ - Repubblica Ceca 10
KH - Cambogia 10
MN - Mongolia 10
PE - Perù 10
ZM - Zambia 10
BF - Burkina Faso 9
BO - Bolivia 9
CI - Costa d'Avorio 9
CU - Cuba 9
EE - Estonia 9
EG - Egitto 9
HN - Honduras 9
KE - Kenya 9
LB - Libano 9
NP - Nepal 9
SD - Sudan 9
BA - Bosnia-Erzegovina 8
BZ - Belize 8
CV - Capo Verde 8
HR - Croazia 8
LT - Lituania 8
ME - Montenegro 8
MG - Madagascar 8
MR - Mauritania 8
MZ - Mozambico 8
NC - Nuova Caledonia 8
PS - Palestinian Territory 8
PY - Paraguay 8
RS - Serbia 8
SI - Slovenia 8
TH - Thailandia 8
ZW - Zimbabwe 8
BE - Belgio 7
CG - Congo 7
CM - Camerun 7
CW - ???statistics.table.value.countryCode.CW??? 7
DJ - Gibuti 7
GA - Gabon 7
Totale 7.147
Salva come PNG Salva come JPEG
Città #
Ashburn 483
Singapore 383
San Jose 299
Fairfield 179
Hong Kong 179
Ho Chi Minh City 157
Hanoi 144
Chandler 134
Santa Clara 121
Beijing 80
Los Angeles 71
Council Bluffs 70
New York 58
Seattle 57
Cambridge 56
Houston 56
Woodbridge 56
Milan 53
Da Nang 50
Padova 49
Dallas 42
Boardman 39
Chicago 39
Ann Arbor 36
Wilmington 35
Helsinki 31
Lauterbourg 30
San Diego 28
Rome 27
Bytom 26
São Paulo 25
Buffalo 24
Hefei 22
Munich 21
Haiphong 20
London 20
Padua 20
North Charleston 18
Orem 18
Medford 17
Princeton 17
Cotonou 16
Frankfurt am Main 16
Nuremberg 15
Turku 15
Baghdad 14
Des Moines 14
Istanbul 14
Montreal 14
Naples 14
Phoenix 13
San José 13
Turin 13
Baku 12
Guangzhou 12
Johannesburg 12
Seoul 12
Venice 12
Washington 12
Amman 11
Amsterdam 11
Bologna 11
Castries 11
Denver 11
Dushanbe 11
Kingston 11
Roxbury 11
The Dalles 11
Tokyo 11
Warsaw 11
Athens 10
Brooklyn 10
Lahore 10
Lusaka 10
Managua 10
Tashkent 10
Abidjan 9
Atlanta 9
Biên Hòa 9
Chennai 9
Dublin 9
Figino 9
Hải Dương 9
Mexico City 9
Mosier 9
Nairobi 9
Paris 9
Phnom Penh 9
Pune 9
Redondo Beach 9
Salt Lake City 9
Stockholm 9
Toronto 9
Ulan Bator 9
Antananarivo 8
Brasília 8
Columbus 8
Elk Grove Village 8
Lappeenranta 8
Las Vegas 8
Totale 3.924
Salva come PNG Salva come JPEG
Nome #
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial 353
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 345
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 307
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 305
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 288
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 285
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 285
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 284
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 266
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 261
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 257
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 253
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 244
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 237
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 232
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 223
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 214
The role of liver kinase B1 in small cell lung cancer: association with prognosis and tumor immune microenvironment features 210
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 210
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 208
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 199
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 199
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer 195
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 191
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 190
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 185
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 185
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis 184
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 183
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 164
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 144
Machine Learning Identifies a Distinct Microbiota Signature in Immune Checkpoint Inhibitor Colitis Compared with Inflammatory Bowel Disease 95
Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort 92
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study 50
Totale 7.523
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.687
article - articoli 20.294
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022268 0 0 0 9 26 52 60 9 13 18 25 56
2022/2023270 31 39 15 38 31 21 5 20 53 6 11 0
2023/2024264 21 21 27 28 17 40 18 24 21 13 22 12
2024/2025966 4 69 46 34 135 17 20 89 78 46 165 263
2025/20264.470 238 285 508 649 344 192 820 292 442 254 247 199
2026/2027853 367 174 174 138 0 0 0 0 0 0 0 0
Totale 7.523